JACOB J. LOKICH, M.D.; CHERIE MOORE, R.N.
To the editor: Reed and colleagues (1) have reported their experience with drug extravasation developing in five of ten patients in whom venous access ports were used for the delivery of dobutamine or cancer chemotherapy. They conclude that use of venous access ports should perhaps be limited to infusions of short duration, defined as less than 1 to 2 hours. Although the mechanism was not detailed in the report, they suggest that the development of extravasation was related to dislodgement of the needle from the access port.
We have used venous access devices in 195 patients in whom we placed
LOKICH JJ, MOORE C. Drug Extravasation in Cancer Chemotherapy. Ann Intern Med. ;104:124. doi: 10.7326/0003-4819-104-1-124_1
Download citation file:
Published: Ann Intern Med. 1986;104(1):124.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use